Rein Therapeutics, a biopharmaceutical company focused on orphan pulmonary and fibrosis treatments, announced that CEO Brian Windsor will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The event will be webcast live and archived for 90 days on Rein's investor website. Rein is advancing LTI-03, a novel synthetic peptide with orphan drug and fast track designations, targeting lung fibrosis and related conditions. This presentation highlights Rein's ongoing efforts to engage investors and showcase its innovative pipeline.
Rein Therapeutics' upcoming presentation coincides with notable activity in the health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell today. Top gainers included INO (Inovio Pharmaceuticals Inc) at USD 2.04 with a 239.48% increase and a typical hold time of 43 days, CLPT (ClearPoint Neuro Inc) at USD 11.71 up 9.54%, and IDXX (IDEXX Laboratories, Inc.) at USD 585.99 up 6.31%, with a typical hold time of 47 days.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
